Actively Recruiting

Phase 2
Phase 3
Age: 18Years - 70Years
All Genders
NCT06447597

A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis.

Led by Shanghai Jiaolian Drug Research and Development Co., Ltd · Updated on 2026-04-30

104

Participants Needed

18

Research Sites

104 weeks

Total Duration

On this page

Sponsors

S

Shanghai Jiaolian Drug Research and Development Co., Ltd

Lead Sponsor

S

Shanghai Pharmaceuticals Holding Co., Ltd

Collaborating Sponsor

AI-Summary

What this Trial Is About

The purpose of this study is to evaluate the efficacy and safety of B007 in subjects with generalized myasthenia gravis.

CONDITIONS

Official Title

A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis.

Who Can Participate

Age: 18Years - 70Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Signed informed consent form
  • Diagnosis of generalized myasthenia gravis
  • Positive serum acetylcholine receptor antibody (AchR-Ab) or MUSK antibody (MUSK-Ab) during screening
  • MG-ADL score of 5 or higher at screening and baseline
  • Receiving at least one stable dose of standard care for generalized myasthenia gravis before randomization and maintaining stable dose during the study
  • Agree to use effective contraception from consent signing to 1 year after last dose; female subjects fertile by investigator must have negative pregnancy test before first dose
Not Eligible

You will not qualify if you...

  • Myasthenia Gravis Foundation of America (MGFA) type I or V
  • Use of prescribed drugs contraindicated for the study
  • Presence or history of specified diseases making participation unsuitable
  • Abnormal examination results deemed unsuitable by investigator
  • History of severe allergic reaction to humanized monoclonal antibodies or allergy to any component of B007
  • Receipt of live vaccine within specified time before first dose or planned after last dose
  • Major surgery or participation in other clinical trials within specified time before screening
  • Pregnant or breastfeeding women
  • Fertile females not agreeing to effective contraception during and 1 year after study
  • Sexually active males not intending to use contraception during and 1 year after study or planning to donate sperm
  • History of alcohol or drug abuse within past 12 months
  • Other conditions making participation unsuitable as judged by researchers

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 18 locations

1

Peking University First Hospital

Beijing, China

Actively Recruiting

2

The First Bethune Hospital of Jilin University

Changchun, China

Actively Recruiting

3

Xiangya Hospital Central South University

Changsha, China

Actively Recruiting

4

Sichuan Provincial People's Hospital

Chengdu, China

Actively Recruiting

5

Nanfang Hospital, Southern Medical University

Guangzhou, China

Actively Recruiting

6

The First Affiliated Hospital, Zhejiang University School of Medicine

Hangzhou, China

Actively Recruiting

7

Shandong Provincial Qianfoshan Hospital

Jinan, China

Actively Recruiting

8

Shandong University Cheeloo College of Medicine

Jinan, China

Actively Recruiting

9

First People's Hospital of Yunnan Province

Kunming, China

Actively Recruiting

10

Jiangxi Provincial People's Hospital

Nanchang, China

Actively Recruiting

11

The Second Affiliated Hospital of Nanchang University

Nanchang, China

Actively Recruiting

12

Shandong University Cheeloo College of Medicine

Qingdao, China

Actively Recruiting

13

Huashan Hospital, Fudan University

Shanghai, China

Actively Recruiting

14

Shenzhen Hospital of University of Hong Kong

Shenzhen, China

Actively Recruiting

15

Renmin Hospital of Wuhan University

Wuhan, China

Actively Recruiting

16

Tongji Medical College of HUST

Wuhan, China

Actively Recruiting

17

Tangdu Hospital

Xi'an, China

Actively Recruiting

18

Affiliated Hospital of Zunyi Medical College

Zunyi, China

Actively Recruiting

Loading map...

Research Team

J

Jianying Xi

CONTACT

H

Huan Yang

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here